Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229658 · ClinicalTrials.gov registry record
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
A clinical trial of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by AstraZeneca.
- Completed
- Registry status
- 1,297
- Enrollment target
- 20
- Study locations
NCT00229658: Completed study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by AstraZeneca.
NCT00229658 is a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 1,297 participants, below the 2,950-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00229658, a study of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 1,297 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.
Primary Outcome
PASH is defined as episodes of hypoglycemia requiring the assistance of another individual (including aid in ingestion of oral carbohydrate); and/or requiring the administration of glucagon injection, intravenous glucose, or other medical intervention. The adjustment period represents the initial 0-3 months of pramlintide treatment
Conditions Studied
Interventions
- DRUG pramlintide acetate
Study Locations (20)
California
- Research Site - Anaheim
- Research Site - Encinitas
- Research Site - Escondido
- Research Site - Fresno
- Research Site - Lafayette
- Research Site - Moreno Valley
- Research Site - Sacramento
- Research Site - Salinas
- Research Site - Santa Barbara
- Research Site - Torrance
- Research Site - Vacaville
Alabama
- Research Site - Birmingham
- Research Site - Montgomery
Colorado
- Research Site - Arvada
- Research Site - Aurora
Florida
- Research Site - Hialeah
- Research Site - Jacksonville
Arizona
- Research Site - Tucson
Connecticut
- Research Site - Norwalk
Delaware
- Research Site - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,297 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-05 |
What the finished NCT00229658 record still lists
NCT00229658 is an observational study that tracks outcomes without assigning an intervention. Its 1,297 participants enrollment target places it among the larger protocols in the corpus, below the 2,950-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (56% lower).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which pramlintide acetate is the first listed.
NCT00229658 names 20 study sites across 7 states, led by California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT00229658 about?
NCT00229658 is a clinical study titled "An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes". This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescrib...
What is the current status of trial NCT00229658?
This trial is currently completed. The enrollment target is 1,297 participants. The study started on 2005-09. Estimated completion is 2008-05.
What conditions does trial NCT00229658 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00229658?
The interventions under investigation include: pramlintide acetate (DRUG).
Who is sponsoring clinical trial NCT00229658?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00229658 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00229658's enrollment target sits among peer trials
1,297 12th of 130 higher than 119 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
RECRUITING
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
- NCT05166694 · 1,300 participants · NA
Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia